BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:57 PM | Browse: 86 | Download: 342
 |
Received |
|
2025-02-05 04:39 |
|
Peer-Review Started |
|
2025-02-05 04:39 |
|
First Decision by Editorial Office Director |
|
2025-03-25 07:10 |
|
Return for Revision |
|
2025-03-25 07:10 |
|
Revised |
|
2025-04-04 08:55 |
|
Publication Fee Transferred |
|
2025-04-11 04:31 |
|
Second Decision by Editor |
|
2025-05-30 02:43 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-30 07:25 |
|
Articles in Press |
|
2025-05-30 07:25 |
|
Edit the Manuscript by Language Editor |
|
2025-06-04 18:36 |
|
Typeset the Manuscript |
|
2025-06-30 01:58 |
|
Publish the Manuscript Online |
|
2025-07-14 12:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Progress in the treatment of duodenal cancer: A comprehensive review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Liang-Gong Liao, Zhi-Guo Xiong and Jun-Jie Hu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Research Projects of Biomedical Center of Hubei Cancer Hospital |
2022SWZX07 |
| the 2023-2024 Annual Scientific Research Project of Traditional Chinese Medicine from Hubei Provincial Administration of Traditional Chinese Medicine |
ZY2023Z005 |
| Health Commission of Hubei Province Scientific Research Project |
WJ2023Z011 |
|
| Corresponding Author |
Jun-Jie Hu, MD, Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zuodaoquan South Road, Wuhan 430079, Hubei Province, China. 791462122@qq.com |
| Key Words |
Duodenal cancer; Surgical resection; Chemotherapy; Targeted therapies; Immunotherapy |
| Core Tip |
Duodenal cancer, a rare gastrointestinal malignancy (< 0.5/100000 incidence), requires multidisciplinary strategies. Endoscopic resection for early-stage tumors improves survival and reduces infection mortality. Advanced cases benefit from surgery and minimally invasive techniques. Chemotherapy and neoadjuvant chemoradiotherapy enhance outcomes. Targeted therapies such as erb-b2 receptor tyrosine kinase 2 (human epidermal growth factor receptor 2)/phosphatidylinositol-3-kinase inhibitors and immunotherapy show transformative potential. Molecular profiling guides precision medicine. International collaboration is critical to optimize biomarker-driven strategies and improve survival. This review integrates innovations in surgery, systemic therapy, and immunotherapy, offering a roadmap for personalized management. |
| Publish Date |
2025-07-14 12:55 |
| Citation |
Liao LG, Xiong ZG, Hu JJ. Progress in the treatment of duodenal cancer: A comprehensive review. World J Gastrointest Oncol 2025; 17(7): 105712 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i7/105712.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i7.105712 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
